MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro
2024 has started on a low for US biotech Anavex Life Sciences, which saw its shares fall sharply this morning after Rett syndrome candidate Anavex 2-73 failed a clinical t
AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan
New data from NHS England has revealed that the waiting list for community health services has topped one million for the first time, with children and young people dispro
The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect newborns and infants from the virus after an advisor
Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower r
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh